The Association of Peak Glycemia and No-Reflow Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention.

IF 2.1 4区医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Cardiology Research and Practice Pub Date : 2026-02-13 eCollection Date: 2026-01-01 DOI:10.1155/crp/9919861

Golrokh Ghaffari, Maryam Mehrpooya, Mohsen Faghihinia, Elnaz Shahmohamadi, Farnoosh Larti, Babak Geraiely

{"title":"The Association of Peak Glycemia and No-Reflow Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention.","authors":"Golrokh Ghaffari, Maryam Mehrpooya, Mohsen Faghihinia, Elnaz Shahmohamadi, Farnoosh Larti, Babak Geraiely","doi":"10.1155/crp/9919861","DOIUrl":null,"url":null,"abstract":"Objective: This study investigates the effect of peak glycemia on the no-reflow phenomenon in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) to examine the relationship between elevated blood glucose (BG) levels and no-reflow.Method: A total of 252 STEMI patients (81.7% male) who underwent PPCI were enrolled. BG was measured by a glucometer every 6 h for 24 h, starting at the time of patient admission. The maximum measured BG was considered the peak glycemic level. A corrected TIMI frame count (CTFC) of less than 27 was used to define the no-reflow phenomenon in this study.Results: 42.4% of participants experienced no flow, with a significant association between this condition and diabetes mellitus, peak glycemia, smoking history, and elevated LDL cholesterol levels. Specifically, peak glycemia levels above 180 mg/dL independently increased the odds of no-reflow occurrence (OR = 8.16, 95% CI = 4.1-16.2, p < 0.001).Conclusion: The importance of monitoring BG levels in STEMI patients, as well as the critical role of a multidisciplinary approach, regardless of diabetic status, in mitigating the risk of no-reflow and improving clinical outcomes, should be highlighted.","PeriodicalId":9494,"journal":{"name":"Cardiology Research and Practice","volume":"2026 ","pages":"9919861"},"PeriodicalIF":2.1000,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12905458/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology Research and Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/crp/9919861","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study investigates the effect of peak glycemia on the no-reflow phenomenon in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI) to examine the relationship between elevated blood glucose (BG) levels and no-reflow.

Method: A total of 252 STEMI patients (81.7% male) who underwent PPCI were enrolled. BG was measured by a glucometer every 6 h for 24 h, starting at the time of patient admission. The maximum measured BG was considered the peak glycemic level. A corrected TIMI frame count (CTFC) of less than 27 was used to define the no-reflow phenomenon in this study.

Results: 42.4% of participants experienced no flow, with a significant association between this condition and diabetes mellitus, peak glycemia, smoking history, and elevated LDL cholesterol levels. Specifically, peak glycemia levels above 180 mg/dL independently increased the odds of no-reflow occurrence (OR = 8.16, 95% CI = 4.1-16.2, p < 0.001).

Conclusion: The importance of monitoring BG levels in STEMI patients, as well as the critical role of a multidisciplinary approach, regardless of diabetic status, in mitigating the risk of no-reflow and improving clinical outcomes, should be highlighted.

Abstract Image

查看原文本刊更多论文

初级经皮冠状动脉介入治疗患者血糖峰值与无血流现象的关系。

目的：探讨血糖峰值对st段抬高型心肌梗死（STEMI）行首次经皮冠状动脉介入治疗（PPCI）患者无血流再流现象的影响，探讨血糖水平升高与无血流再流的关系。方法：共纳入252例行PPCI的STEMI患者（81.7%为男性）。从患者入院时开始，每6小时用血糖仪测量BG，持续24小时。测得的最大BG被认为是血糖峰值。在本研究中，校正后的TIMI帧数（CTFC）小于27被用来定义无回流现象。结果：42.4%的参与者没有血流，这种情况与糖尿病、血糖峰值、吸烟史和低密度脂蛋白胆固醇水平升高有显著关联。具体来说，血糖峰值高于180 mg/dL单独增加无血流倒流发生的几率（OR = 8.16, 95% CI = 4.1-16.2, p < 0.001）。结论：应强调STEMI患者监测BG水平的重要性，以及多学科方法在减轻无再流风险和改善临床结果方面的关键作用，无论糖尿病状态如何。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cardiology Research and Practice Medicine-Cardiology and Cardiovascular Medicine

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Cardiology Research and Practice is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies that focus on the diagnosis and treatment of cardiovascular disease. The journal welcomes submissions related to systemic hypertension, arrhythmia, congestive heart failure, valvular heart disease, vascular disease, congenital heart disease, and cardiomyopathy.